微RNA (miRNA) 作为局部高级和转移性胃癌的预后和预测生物标志物的探索性分析
Charles L1, Yadav Nisha1, Babu Vishva1
1Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND.
Cureus
|March 12, 2026
概括
像miR-29c,miR-27a和miR-25这样的微RNA (miRNA) 显示出作为晚期胃癌的生物标志物的潜力. 低miR-29c与转移相关,而miR-25和miR-27a水平预测治疗反应和生存结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 微RNAs (miRNAs) 作为瘤基因或瘤抑制剂在癌症发病过程中受到影响.
- miRNAs在治疗反应和患者生存结果中发挥着关键作用.
- 识别特定的miRNA可以帮助理解和管理晚期胃癌.
研究的目的:
- 识别作为预后和预测生物标志物的微RNA (miRNA).
- 为了研究特定的瘤抑制酶和瘤抑制剂miRNAs在胃癌中的作用.
- 为了将miRNA表达与局部晚期和转移性胃癌的临床因素相关联.
主要方法:
- 对50名胃癌患者的组织进行前性探索性研究.
- 定量实时逆转录聚合酶链反应 (qRT-PCR) 来测量miRNA的表达.
- 分析miRNA表达与临床因素之间的关联,包括转移和治疗反应.
主要成果:
- 观察到miR-29c,miR-27a和miR-25的差异表达.
- 较低的miR-29c表达与转移的增加有关 (P = 0.03).
- 下调的miR-25与缺少腹膜干扰和肝转移相关 (P < 0.0001,P < 0.005).
- 高的miR-27a表达表明化学疗法反应更好 (P = 0.04),但整体存活率较差 (P = 0.02).
结论:
- 在晚期胃癌中,miR-29c,miR-27a和miR-25的调节不同.
- 这些miRNAs显示出作为预测和预后生物标志物的潜力.
- 需要进一步的验证研究来确认它们在胃癌管理中的临床实用性.
相关概念视频
MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs
24.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K


